Mustang Bio stock: Q3 net loss widens to $964,000
Published on 11/19/2026 at 03:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSCash runway and pipeline shape outlook
- Management expects cash to fund operations for at least twelve months from the filing date.
- Mustang Bio is preparing a possible MB-109 investigator-sponsored study at City of Hope in the first quarter of 2027.
- Nasdaq granted the company an additional compliance period through April 12, 2027.
Mustang Bio reported a third-quarter net loss of $964,000 for the period ended September 30, 2026, compared with a loss of $468,000 a year earlier. The company filed its quarterly report on November 5. Its Form 10-Q showed no product revenue and higher operating expenses during the quarter.
Losses rise as development continues
Operating expenses reached $1.058 million, compared with $624,000 in the year-ago quarter. Research and development expense was $208,000, while general and administrative expense was $850,000. Interest income of $94,000 partly offset the operating loss.
For the first nine months of 2026, Mustang Bio reported a net loss of $2.991 million, compared with $1.383 million in the same period of 2025. Net cash used in operating activities declined to $2.851 million from $3.546 million, while cash and cash equivalents stood at $14.276 million at September 30.
Pipeline remains the key catalyst
Mustang Bio said its cash and cash equivalents should fund operations for at least twelve months from the financial statements' issuance date. The company is exploring a possible investigator-sponsored MB-109 study at City of Hope in the first quarter of 2027 and expects research and development costs to increase if the program advances.
MB-101 CAR T and MB-108 oncolytic virus programs remain in development for difficult-to-treat cancers. Treatment in the MB-101 and MB-108 Phase 1 trials has been completed, with long-term safety follow-up continuing.
Nasdaq compliance remains a risk
Mustang Bio said it had not regained compliance with Nasdaq's minimum bid-price requirement by October 12, 2026. Nasdaq granted an additional grace period through April 12, 2027, during which the company must meet the exchange's requirements or face potential delisting. Mustang said it may consider a reverse stock split if necessary.
Clinical-stage biotechnology company
Mustang Bio is a US clinical-stage biopharmaceutical company focused on developing cell therapies and oncolytic virus treatments for difficult-to-treat cancers. Its pipeline includes CAR T programs such as MB-101 and MB-109 and the MB-108 oncolytic virus program. The company funds research and development with equity financing and seeks to license or commercialize successful candidates.
Mustang Bio at a glance
- Company: Mustang Bio, Inc.
- Ticker: MBIO
- Exchange: Nasdaq Capital Market
- Reporting period: Third quarter ended September 30, 2026
- Headquarters: Waltham, Massachusetts, United States
The S&P 500 provides the broader US market backdrop for biotechnology investors.
